November 2003 Volume 10 Number 4. Expiration Date June 29, 2017
|
|
- Roderick Griffin
- 5 years ago
- Views:
Transcription
1 November 2003 Volume 10 Number 4
2 No responsibility is assumed by Elsevier, its licensors or associates for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. November 2003, Vol. 10, No. 4 The Journal of the American Association of Gynecologic Laparoscopists Evaluation of HydroThermAblator and Rollerball Endometrial Ablation for Menorrhagia 3 Years after Treatment Milton H. Goldrath, M.D. Abstract (J Am Assoc Gynecol Laparosc 10(4): , 2003) Study Objective. To compare the safety and efficacy of endometrial ablation using HydroThermAblator (HTA) and rollerball (RB) for treatment of menorrhagia. Design. Prospective, randomized, multicenter study (Canadian Task Force classification I). Setting. Nine private practice and university centers in the United States. Patients. Two hundred seventy-six women. Intervention. Hysteroscopic endometrial ablation with the HTA(187 women) and RB (89). Measurements and Main Results. Bleeding was assessed by pictorial diaries for 12 months, with patient interviews at 24 and 36 month. Amenorrhea rates, reduction of bleeding to normal levels or less, and patient satisfaction were tracked for 36 months, with rates in the HTAgroup of 53%, 94%, and 98% and in the RB group of 46%, 91%, and 97%, respectively. Conclusion. Endometrial ablation with the HTAis a safe, effective, and durable treatment of menorrhagia in a broad patient population. It offers advantages over RB by reducing anesthesia requirements, reducing operating time, and eliminating risks of excessive fluid absorption, and is more easily learned. Menorrhagia is a significant clinical problem for premenopausal women, accounting for millions of visits annually to gynecologists in the United States. Often patients are provided relief through medical therapy; however, hysterectomy is the final solution for many women. Although the minimally invasive alternative of hysteroscopic endometrial ablation has been available for 2 decades, it is estimated that at least 25% of hysterectomies performed are to relieve excessive menstrual bleeding from benign causes. This is due in part to the high technical proficiency necessary to perform resectoscopic ablation, and to failure of some global techniques to achieve a high rate of amenorrhea. In addition, even the skilled hysteroscopic surgeon must remain vigilant with regard to the risk of absorption of excessive amounts of nonphysiologic solutions used to maintain working space within the uterine cavity during resectoscopic procedures. In an effort to overcome the level of proficiency required to treat the entire uterine cavity safely and effectively by traditional hysteroscopic ablation techniques, the HydroThermAblator (HTA) system (Boston Scientific, Natick, MA) was developed. 1 A multicenter, randomized, phase III clinical trial with 1-year follow-up was conducted as a requirement for receipt of Food and Drug Administration (FDA) approval of the system in the United States. 2 This report extends the follow-up of clinical outcomes from the study of these patients to 3 years. Materials and Methods This randomized study was designed to evaluate the safety and efficacy of endometrial ablation with the HTA system compared with traditional hysteroscopic rollerball technique. Institutional review board approval was obtained. Patients were screened at 9 centers by 14 investigators to determine if they satisfied inclusion criteria: age 30 to 50 years, childbearing completed, history of at least 3 months of excessive bleeding documented by a pictorial bleeding assessment chart (PBAC), 3 uterine cavity measuring between 4 and 10.5 cm, and failed, not tolerated, or refused medical therapy. Exclusion criteria were active or symptomatic pelvic inflammatory disease, intramural myomas greater that 4 cm, submucosal myomas or polyps, and fully septate uterus. All patients had an endometrial biopsy and cervical cytology to rule out hyperplasia and malignancy. Those who met inclusion criteria were randomized by computergenerated block on a 2:1 basis (HTA:rollerball), and received From the Department of Obstetrics and Gynecology, Wayne State University, Detroit, Michigan. Corresponding author Milton H. Goldrath, M.D., 5777 West Maple Road, Suite 200, West Bloomfield, MI Submitted February 3, Accepted for publication March 31, 2003 Supported by BEI Medical Systems, a Boston Scientific Company, Natick, Massachusetts. The author has a financial interest in the HydroThermAblator. Reprinted from the JOURNAL OF THE AMERICAN ASSOCIATION OF GYNECOLOGIC LAPAROSCOPISTS, November 2003, Vol. 10 No The American Association of Gynecologic Laparoscopists. All rights reserved. This work may not be reproduced in any form or by any means without written permission from the AAGL. This includes but is not limited to, the posting of electronic files on the Internet, transferring electronic files to other persons, distributing printed output, and photocopying. To order multiple reprints of an individual article or request authorization to make photocopies, please contact the AAGL. 505
3 HTA and Rollerball Endometrial Ablation 3 Years after Treatment Goldrath a single injection of depot leuprolide acetate 7.5 mg on day 21 ± 2 of their cycle. Treatment was scheduled between 19 and 27 days later, provided menses had ensued. Based on an estimate of successful reduction of excessive menstrual bleeding to normal levels or less in 80% of women treated by rollerball ablation, it was determined that a sample of 276 subjects was required to demonstrate equivalence if the success rate in the two groups did not differ by more than 20%. Other assumptions were a two-sided α of 5%, power of 90%, and dropout rate of 12%, all within the 2:1 ratio of HTA versus rollerball. Choice of treatment setting (office-outpatient surgery center, hospital operating room) and anesthesia regimen (paracervical block alone or with intravenous sedation, general inhalation anesthesia) were decided mutually by patient and physician. The primary end point of the study at 12 months after treatment was reduction of PBAC scores to 75 or less (established by the FDA) between HTA treatment group and the control group (rollerball). Aquality of life questionnaire 4 was administered for pretreatment and posttreatment secondary analyses. Patients visited the treating physician for follow-up 2 weeks and 3, 6, and 12 months after treatment. Further follow-up was done at 2 and 3 years after treatment through interviews if patients were not examined. The HTA Device The HTA system is described elsewhere. 2 Its control mechanisms are housed in a compact console mounted on a mobile cart (Figure 1). Circulation of fluid (0.9% saline solution) is controlled by gravity, based on the height of the fluid container above the patient s uterus, with actual intrauterine pressure reduced from hydrostatic pressure by the effect of the evacuation pump that recirculates fluid to the elevated reservoir. The fluid reservoir, mounted on the unit s dedicated intravenous pole, is adjusted to a height of 115 cm (45 inches) above the patient s uterus to provide a net intrauterine pressure in the range of 50 to 55 mm Hg, well below the minimum pressure of 70 mm Hg required to open the fallopian tubes. 5 With the operating table at a typical height for hysteroscopic procedures, and with an average-size patient, the uterus is approximately 85 cm (34 inches) above the floor. The fluid reservoir may be elevated to a maximum height of 221 cm (87 inches) above the floor when the connecting tubing set is fully extended. Consequently, maximum net intrauterine pressure obtainable during HTA treatment is less than 70 mm Hg. After the cervix is dilated to accept the insulated hysteroscopic sheath (7.8 mm outer diameter; Figure 2), which accommodates hysteroscope telescopes 3 mm or smaller, flow of room-temperature saline is started to allow visualization of the cervical canal and uterine cavity. As a safety feature, the HTA system is calibrated to detect loss of as little as 10 ml of saline from closed-loop circulation, so care is taken to not overdilate the cervix to ensure a good seal. Diagnostic hysteroscopy is performed with the HTA sheath to ensure absence of unrecognized pathology, and to identify the tubal ostia as landmarks indicating that the sheath has not been placed in a false passage. Only then is heating of circulating saline begun, with a therapy cycle of 10 FIGURE 1. The HTAcontrol unit, dedicated intravenous pole, and mobile cart. FIGURE 2. HTAinsulated hysteroscopic sheath. minutes. On completion of the therapy cycle, the operator is prompted to wait for the 1-minute cooling cycle to finish, followed by a prompt that the sheath may be removed from the patient. Hysteroscopic visualization is maintained 506
4 November 2003, Vol. 10, No. 4 The Journal of the American Association of Gynecologic Laparoscopists throughout the procedure, allowing full appreciation of blanching caused throughout the cavity, even in the presence of cavity asymmetry. Results Of 276 women originally randomized, 269 received at least partial treatment. Complete treatments under the protocol were received by 177 patients in the HTA group and 85 in the rollerball group. Of seven incomplete HTA treatments due to technical difficulties with the device, three were converted to rollerball treatment. More patients underwent HTA (41%) than rollerball treatment (22%) in the office setting; one site had a fully equipped operating room. Similarly, more patients received local anesthesia, with or without sedation, for HTA (45%) than for rollerball treatment (22%). These factors contributed to the median time spent in the recovery room for the HTA group of only 70 minutes. Intraoperative adverse events were limited, with two cervical lacerations (2.4%) in the rollerball group and two external burns (1.1%) in the HTA group. These burns, one on the buttocks and one on the upper thigh, were due to prolonged contact with the tubing that carries heated saline from the control unit to the hysteroscopic sheath; an insulating cover has been added to this tubing to eliminate the problem from the commercial version of the device. One of two women with cervical lacerations in the rollerball group developed a serious complication; 1 day after ablation she experienced fever, nausea, vomiting, and diarrhea and was admitted to the hospital. Laboratory tests indicated gram-negative septicemia. The woman responded to antibiotic therapy and was discharged 6 days later. Postoperatively, three women had endometritis (HTA 2, rollerball 1), seven had urinary tract infections (HTA 5, 2.7%; rollerball 2, 2.4%), and seven had hematometra (HTA 2, 1.1%; rollerball 5, 5.9%) that was resolved by cervical dilatation during an office visit. During the 2-week followup visit at four of the nine investigational sites, changes in the appearance of cervical epithelium were noted during examination of 13% of HTA-treated patients, although no patients reported symptoms. These changes were thought to be related to thermal effects of HTA treatment; one investigator accounted for 48% of the observations. No medical or surgical intervention was given to any of these patients, and in every case the cervix appeared normal at the 1-month visit. The two women in the HTA group with hematometra were not among these patients. At 1 year, 12 patients who had received complete treatment were lost to follow-up, 10 (5.6%) from the HTA group, including 2 accidental deaths unrelated to surgery, and 2 (2.4%) from the rollerball group. Two patients in the HTA group had hysterectomies during the first year, which provided a per protocol population of 250 patients (167 HTA, 83 rollerball) at 12 months. At 2 years, the per protocol population was 220 patients (151 HTA, 74 rollerball), and overall, 203 (77%) of the original 262 patients treated per protocol (135 HTA, 68 rollerball) were available for evaluation of clinical efficacy data at 3 years (Table 1). Pretreatment PBAC diary scores ranged from 143 to 8662 (mean ± 787.6) for the HTA group and from 151 to 4140 (mean ± 565.2) for the rollerball group. At 12 months, 40% (66/167) of the HTA group had scores indicating no bleeding-amenorrhea (PBAC zero) compared with 51% (42/83) of the control group. Bleeding was reduced to the FDA-mandated PBAC diary score of 75 or lower as the indicator of treatment success for comparison in 77% (128/167) and 82% (68/83) of HTA and rollerball groups, respectively. Normal bleeding, as indicated by a PBAC score of 100 or below, was achieved by 82% of HTA and 85% of rollerball patients 2 (Table 2). At 24 months, complete elimination of menstrual bleeding (amenorrhea) was reported by 46% (70/151) and 46% (34/74) of women, respectively. Reduction of bleeding to normal levels or less was reported by 92% (139/151) and 92% (68/74), respectively. Results at 36 months were consistent with those at 24 month; amenorrhea in 53% (72/135) of HTA patients and 46% (31/68) of rollerball patients (Figure 3). Further consistency is shown in reduction of bleeding to normal levels or less of 94% (127/135) and 91% (62/68), respectively (Figure 4). In addition, 98% of HTA patients and 97% of rollerball patients reported satisfaction with treatment at 36 months. Hysterectomies, repeat ablations, and other interventions for bleeding were tracked for 3 years. Hysterectomies were performed on 16 (9%) of 177 women in the HTA group and 5 (6%) of 85 women in the rollerball group, repeat ablations were performed on 3 (2%) and 3 (4%), respectively, and uterine artery embolization for myomas in 2 (1%) HTA patients. Reasons for hysterectomy were available for 10 TABLE 1. Sequence of Patients Dropped from Study 12 Months 24 Months 36 Months Totals a Reason HTA RB HTA RB HTA RB HTA RB Hysterectomy a a 5 Repeat ablation Other Lost 6 a 2 a 9 7 a a 14 a Totals a 17 a HTA = HydroThermAblator system; RB = rollerball. a Overall totals reflect adjustment of earlier accounting errors and return of patients at 24 and 36 months. 507
5 HTA and Rollerball Endometrial Ablation 3 Years after Treatment Goldrath TABLE 2. Menstrual Status at 12, 24, and 36 Months 12 Months 24 Months 36 Months % (no.) % (no.) % (no.) HTA RB HTA RB HTA RB Menstrual Status (n = 167) (n = 83) (n = 151) (n = 74) (n = 135) (n = 68) Amenorrhea 40 (66) 51 (42) 46 (70) 46 (34) 53 (72) 46 (31) Normal 82 (137) 85 (71) 92 (139) 92 (68) 94 (127) 91 (62) Excessive 18 (30) 15 (12) 8 (12) 8 (6) 6 (8) 9 (6) HTA = HydroThermAblator system; RB = rollerball. FIGURE 3. Amenorrhea rates at 12, 24, and 36 months. patients: persistent pain (5), menorrhagia (3), benign pelvic mass (1), and endometriosis (1). Pretreatment PBAC scores (range , median 490), age (range yrs, median 40 yrs), and body mass index (range kg/m2, median 29 kg/m2) had no predictive value for final outcome. Overall success, considering women with normal bleeding or less and without repeat ablations, hysterectomies, or other interventional procedures, through 36 months of follow-up was 81.4% (127/156) for HTA and 81.6% (62/76) for rollerball. Discussion As with data for 1-year outcomes, analysis of outcomes at 3 years supports the conclusion that endometrial ablation performed with the HTA system is equivalent in efficacy to rollerball ablation. This is true for both patients whose menstrual bleeding was eliminated (amenorrhea) as well as for those whose bleeding was reduced to normal levels or less. In addition, the long-term stability of outcomes of HTA was achieved by physicians with only modest experience with the system. This is in contrast to the considerable experience with rollerball technique they brought to the study. Reduction in Janssen diary scores and amenorrhea rates are the most objective basis for comparison of treatment outcomes, but analysis of responses to a quality of life assessment questionnaire provides a view of a patient s sense of well-being and satisfaction with treatment. These questionnaires were completed by patients before and 12, 24, and 36 months after treatment. Both groups had essentially similar improvements regarding duration and regularity of menstruation, cycle interval, and interference with work, leisure pursuits, sexual activity, and the need to be confined to bed. Before treatment, 58.5% of the HTA group and 67.5% of the rollerball reported heavy bleeding of 4 days duration or longer. Such heavy bleeding was reported by 8%, 6.2%, and 4.4% of the HTA group at 12, 24, and 36 months, and by 8.8%, 2.8%, and 3.7% of the rollerball group, respectively. In addition, menstrual bleeding was reported to interfere with work and other normal activities by 89.6% and 90.3% of the HTA and rollerball groups 508
6 November 2003, Vol. 10, No. 4 The Journal of the American Association of Gynecologic Laparoscopists FIGURE 4. Reduction of bleeding to normal or less (PBAC <100 at 12 mo; patient response at 24 and 36 mo). (Figure 5), with over half of women in both groups losing at least 1 day of work a month. After treatment, 84.9%, 89.0%, and 91.2 % of HTA group and 97%, 88.8%, and 92.6% of the rollerball group reported that menstrual bleeding had no effect at all on work or other normal activities at 12, 24, and 36 months; only 6.8%, 5.5%, and 5.1% versus 3.0%, 2.8%, and 5.6% reported continuing loss of work due to menstrual bleeding at 12, 24, and 36 months. These changes in significant lifestyle issues support satisfaction with HTA and rollerball treatment as reported by 98% and 96% of women, respectively, 36 months after treatment (Figure 6). As with all procedures, the physician should appreciate certain nuances before performing HTA to ensure maximum safety and effectiveness. The cervix should be carefully dilated to avoid having fluid leak around the hysteroscope sheath. This translates to dilatation up to but not beyond 8 mm (24F). An additional tenaculum can be applied at either the 3 or 9 o clock position after the tip of the sheath is positioned in the lower uterine segment, just inside the internal cervical os. This is in addition to the tenaculum typically applied at 12 o clock to stabilize the cervix and provide countertraction while introducing instruments. An effective cervical seal can be accomplished even in women with a patulous cervix. After FDA approval for marketing of the HTA system, clinical users reported placement of an EndoLoop (Ethicon EndoSurgery, New Brunswick, NJ) around the patulous cervix before introducing the HTA FIGURE 5. Bleeding interfering with work and normal activities. 509
7 HTA and Rollerball Endometrial Ablation 3 Years after Treatment Goldrath FIGURE 6. Patient satisfaction with treatment. sheath. The suture loop is tightened after the sheath is positioned and before starting fluid heating to provide an effective seal, allowing the procedure to be completed uneventfully. A vaginal speculum should be kept in position throughout the procedure to allow observation of the junction of the sheath with the cervix. Initial concerns about a risk of heated saline escaping from the fallopian tubes and causing injury are mitigated by the HTA system s low-pressure fluid delivery and fluid volume monitoring, and no such occurrence was observed during this trial or reported in over 10,000 HTA procedures performed worldwide. The HTA procedures performed during this trial under local anesthesia alone or with sedation (45%) support the conclusion that the lining of the uterus is insensitive to heat, and that the low pressure used causes little stretch receptor activity. The key to patient tolerance of HTA treatment with minimal anesthesia is effective administration of a paracervical block, followed by an adequate pause for the anesthetic to take effect before dilating the cervix. Pretreatment with nonsteroidal analgesics is common, but no data exist comparing this with placebo controls. Because circulating heated saline delivers heat to target tissue, it contacts the entire lining of the uterine cavity. This implies that heat can be effectively delivered to all areas in an asymmetrically shaped uterine cavity, or in a cavity distorted by moderate-size myomas, providing both tubal ostia are visible on hysteroscopic examination. As such, it would be anticipated that HTA treatment might be a more effective choice for such patients, in contrast to a tissue-heating mechanism that requires direct contact with the surface of a fixed-shape device. Because fluid is recirculated at a rate of approximately 300 ml/minute, its therapeutic temperature within the cavity is easily maintained. Although uterine volume typically ranges from 10 to 30 ml, variations to even 60 ml present no technical limitation for the HTA system s heating capabilities, and were not a reason for limiting uterine sounding depth to 10.5 cm in this study. Long-term follow-up is important to document the stability of the results and to indicate that this is not just a shortterm respite from hysterectomy. The 5-year follow-up in the thermal balloon study showed this, although there were subtle differences in patient population and inclusion criteria compared with this study. 6 Conclusion Long-term follow-up shows that HTA endometrial ablation can be performed safely and effectively by physicians with minimal experience. The technical proficiency necessary to perform the procedure can be gained easily and quickly, as indicated by 10 of the 14 investigators whose first HTA procedures were performed in patients in this phase III trial, whereas the 4 other investigators had only limited experience gained during phase II trials. The only technical prerequisite is routine diagnostic hysteroscopy skill. The low rate of further treatment, repeat ablations or hysterectomy, supports the expectation that HTA endometrial ablation can result in a considerable reduction in the costs of caring for patients with menorrhagia. Longterm results of HTA endometrial ablation are consistent with results obtained from expertly performed rollerball ablation. The following clinical investigators participated in this study: M. Weisberg, Philadelphia, PA; J. Berman, Novi, MI; P. Brooks, Los Angeles, CA; J. Cooper, Phoenix, AZ; R. Gimpelson, Chesterfield, MO; A. Greenstein, Novi, MI; R. Houck, Phoenix, AZ; D. Iddenden, Philadelphia, PA; J. Krotec, Philadelphia, PA; F. Loffer, Phoenix, AZ; B. Love, Montgomery, AL; A. Luciano, New Britain, CT; R. McCorvey, Montgomery, AL; and F. Sauer, New Britain, CT. 510
8 November 2003, Vol. 10, No. 4 The Journal of the American Association of Gynecologic Laparoscopists References 1. Goldrath MH, Barrionuevo M, Husain M: Endometrial ablation by hysteroscopic instillation of hot saline solution. J Am Assoc Gynecol Laparosc 4: , Corson SL: A multicenter evaluation of endometrial ablation by HydroThermAblator and rollerball for treatment of menorrhagia. J Am Assoc Gynecol Laparosc 8: , Janssen CAH, Scholten PC, Heintz APM: A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 85: , Ruta DA, Garratt AM, Chadha YC, et al: Assessment of patients with menorrhagia: How valid is structured clinical history as a measure of health status? Qual Life Res 4:33-44, Baker VL, Adamson GD: Threshold intrauterine perfusion pressures for intraperitoneal spill during hydrotubation and correlation with tubal disease. Fertil Steril 64: , Loffer FD: Three-year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. J Am Assoc Gynecol Laparosc 8:48 54, 2001 This reprint is provided with the support of Boston Scientific. 511 WH AA APR 2017
Endometrial ablation was developed as a uterinesparing
Minimally Invasive Device Complications and Use Outside of the Manufacturers Instructions Jill Brown, MD, MPH, and Ken Blank, MD OBJECTIVE: To review the U.S. Food and Drug Administration (FDA) Manufacturer
More informationEndometrial Ablation. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Endometrial Ablation Page: 1 of 10 Last Review Status/Date: December 2012 Endometrial Ablation
More informationOriginal Policy Date
MP 4.01.01 Endometrial Ablation Medical Policy Section OB/Gyn/Reproduction Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy
More informationEndometrial tissues have amazing
SURGICAL TECHNIQUES PHILLIP BRZOZOWSKI, MD, and JAMES H. LIU, MD 4 global ablation devices: Efficacy, indications, and technique Newer endometrial ablation technologies are easy to learn, and high efficacy
More informationPreventing hysterectomies for dysfunctional uterine bleeding with the HTA : a survival analysis
Gynecol Surg (2007) 4:39 43 DOI 10.1007/s10397-006-0244-7 ORIGINAL ARTICLE Preventing hysterectomies for dysfunctional uterine bleeding with the HTA : a survival analysis Etienne Ciantar & Kevin Jones
More informationVirtaMed GynoS hysteroscopy Module descriptions
VirtaMed GynoS hysteroscopy Module descriptions VirtaMed AG Rütistr. 12, 8952 Zurich Switzerland info@virtamed.com www.virtamed.com Phone: +41 44 500 9690 Table of contents Table of contents... 1 Essential
More informationEvidence Based Guideline Intrauterine Ablation or Resection of the Endometrium
Evidence Based Guideline Intrauterine Ablation or Resection of the Endometrium File Name: intrauterine_ablation_or_resection_of_the_endometrium Guideline Number: EBG.OBGYN3030 Origination: 4/1993 Last
More informationENDOMETRIAL ABLATION: TRENDS AND CHALLENGES IN 2017
ENDOMETRIAL ABLATION: TRENDS AND CHALLENGES IN 2017 Philippe Laberge MD FRCSC ACGE Professor Obstetrics and Gynecology Laval University Quebec, Canada Disclosures I have used products or done clinical
More informationBENEFIT APPLICATION BLUECARD/NATIONAL ACCOUNT ISSUES
Medical Policy MP 4.01.04 BCBSA Ref. Policy: 4.01.04 Last Review: 08/30/2017 Effective Date: 08/30/2017 Section: OB/GYN Reproduction End Date: 08/19/2018 Related Policies 4.01.11 Occlusion of Uterine Arteries
More informationINTERVENTIONAL PROCEDURES PROGRAMME
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of balloon thermal endometrial ablation (Cavaterm) Introduction This overview has been prepared
More informationHysteroscopic Endometrial Destruction, Optimum Method for Preoperative Endometrial Preparation: A Prospective, Randomized, Multicenter Evaluation
SCIENTIFIC PAPER Hysteroscopic Endometrial Destruction, Optimum Method for Preoperative Endometrial Preparation: A Prospective, Randomized, Multicenter Evaluation O. Shawki, MD, A. Peters, DO, S. Abraham-Hebert,
More informationLong-term Results in the Treatment of Menorrhagia and Hypermenorrhea With a Thermal Balloon Endometrial Ablation Technique
Longterm Results in the Treatment of Menorrhagia and Hypermenorrhea With a Thermal Balloon Endometrial Ablation Technique L. Mettler, Prof Dr Med SCIENTIFIC PAPER ABSTRACT Background and Objectives: Evaluation
More informationMEDICAL POLICY SUBJECT: ENDOMETRIAL ABLATION
MEDICAL POLICY PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationLaparoscopy-Hysteroscopy
Laparoscopy-Hysteroscopy Patient Information Laparoscopy The laparoscope, a surgical instrument similar to a telescope, is inserted through a small incision (cut) in the belly button during laparoscopy.
More informationHIGH-DEFINITION HYSTEROSCOPY FOR A HIGH STANDARD OF CARE.
HIGH-DEFINITION HYSTEROSCOPY FOR A HIGH STANDARD OF CARE. Our next-generation TruClear hysteroscopes were designed with your technique and the patient experience in mind TruClear Elite Hysteroscope Mini
More informationINTERVENTIONAL PROCEDURES PROGRAMME
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of microwave endometrial ablation Introduction This overview has been prepared to assist
More informationEndometrial Ablation. Description
Subject: Endometrial Ablation Page: 1 of 12 Last Review Status/Date: September 2016 Endometrial Ablation Description Endometrial ablation is a potential alternative to hysterectomy for abnormal uterine
More informationCorporate Medical Policy
Corporate Medical Policy Intrauterine Ablation or Resection of the Endometrium File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intrauterine_ablation_or_resection_of_the_endometrium
More informationIMPORTANT REMINDER DESCRIPTION
Medical Policy Manual Surgery, Policy No. 01 Endometrial Ablation Next Review: February 2019 Last Review: September 2018 Effective: October 1, 2018 IMPORTANT REMINDER Medical Policies are developed to
More informationName of Policy: Endometrial Ablation
Name of Policy: Endometrial Ablation Policy #: 453 Latest Review Date: July 2014 Category: Surgical Policy Grade: B Background/Definitions: As a general rule, benefits are payable under Blue Cross and
More informationSIMPLE SAFE EFFECTIVE. Your Solution to Outpatient Ablation
SIMPLE SAFE EFFECTIVE Your Solution to Outpatient Ablation WWW.THERMABLATE-EAS.COM SIMPLE Unique, fully automated design continually controls parameters of time, temperature and pressure to ensure consistent
More informationExcessive menstrual blood loss
Ian Chilcott Excessive menstrual blood loss >80mls - That interferes with physical, emotional, social and material quality of life 1 in 20 women aged 30 to 49 years consult their GP each year with menorrhagia
More informationLaparoscopy and Hysteroscopy
AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE Laparoscopy and Hysteroscopy A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction of
More informationGLOBAL ENDOMETRIAL ABLATION TECHNOLOGY
GLOBAL ENDOMETRIAL ABLATION TECHNOLOGY Training: Part 1 Anatomy and Physiology Female Anatomy Normal Uterus Female Anatomy Normal Uterus Female Anatomy Uterine Positions Abnormal Uterus Retroflexed Normal
More informationComplications from Hysteroscopic Distending Media
Complications from Hysteroscopic Distending Media FACOG Medical Director of the AAGL Advancing Minimally Invasive Gynecology Worldwide Disclosure I have no financial relationships to disclose.. Objective
More informationSTOP/START. On the Web. 12 intraoperative videos from Dr. Garcia, at
Diagnostic hysteroscopy spies polyp previously missed on transvaginal ultrasound and dilation and curettage. STOP performing dilation and curettage for the evaluation of abnormal uterine bleeding START
More informationLong-term economic evaluation of resectoscopic endometrial ablation versus hysterectomy for the treatment of menorrhagia Hidlebaugh D A, Orr R K
Long-term economic evaluation of resectoscopic endometrial ablation versus hysterectomy for the treatment of menorrhagia Hidlebaugh D A, Orr R K Record Status This is a critical abstract of an economic
More informationSubject Index. Cavaterm, endometrial ablation complications 146, 150 contraindications 152 cost analysis compared with hysterectomy
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Abnormal uterine bleeding, see also Adenomyosis, Endometrial cancer, Menorrhagia dilatation and curettage 21, 22, 25 hysteroscopy of premenopausal women anesthesia
More informationBipolar Radiofrequency Endometrial Ablation Compared With Hydrothermablation for Dysfunctional Uterine Bleeding A Randomized Controlled Trial
Bipolar Endometrial Ablation Compared With Hydrotherm for Dysfunctional Uterine Bleeding A Randomized Controlled Trial Josien P.M. Penninx, MD, Ben Willem Mol, MD, Ruben Engels, MD, Minouche M.E. van Rumste,
More informationMedical Policy. MP Endometrial Ablation
Medical Policy MP 4.01.04 BCBSA Ref. Policy: 4.01.04 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: OB/GYN Reproduction End Date: 01/25/2019 Related Policies 4.01.11 Occlusion of Uterine Arteries
More informationREPRODUCTIVE ENDOCRINOLOGY
REPRODUCTIVE ENDOCRINOLOGY FERTILITY AND STERILITY VOL. 82, NO. 1, JULY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Treatment
More informationHysteroscopic polypectomy in 240 premenopausal and postmenopausal women
Hysteroscopic polypectomy in 240 premenopausal and postmenopausal women Sangchai Preutthipan, M.D., and Yongyoth Herabutya, F.R.C.O.G. Department of Obstetrics and Gynaecology, Faculty of Medicine, Ramathibodi
More informationMedical Management of Fibroids Esmya. Dr Paula Briggs Consultant in Sexual and Reproductive Health
Medical Management of Fibroids Esmya Dr Paula Briggs Consultant in Sexual and Reproductive Health Treatment options for Uterine Fibroids ESMYA Selective Uterine Artery Embolisation Fibroid ablation (hysteroscopic
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): January 28, 2014 Effective Date: April 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationJSLS. Combining Myoma Coagulation with Endometrial Ablation/Resection Reduces Subsequent Surgery Rates. Herbert A. Goldfarb, MD ABSTRACT INTRODUCTION
JSLS Combining Myoma Coagulation with Endometrial Ablation/Resection Reduces Subsequent Surgery Rates Herbert A. Goldfarb, MD ABSTRACT Background: This study compares results of endometrial ablation alone
More informationReoperative Hysteroscopic Surgery in the Management of Patients Who Fail Endometrial Ablation and Resection
Study Objective. To determine the safety and efficacy of reoperative hysteroscopic surgery for women who fail endometrial ablation and resection. Design. Retrospective chart review and follow-up (Canadian
More informationNational inpatient diagnostic hysteroscopy survey
Gynecol Surg (2010) 7:53 59 DOI 10.1007/s10397-009-0508-0 CLINICAL PRACTICE National inpatient diagnostic hysteroscopy survey Sherif Tawfeek & Peter Scott Received: 21 June 2009 /Accepted: 9 July 2009
More informationFor personal use only. Endometrial ablation devices: How to make them truly safe
For mass reproduction, content licensing and permissions contact Dowden Health Media. Michael S. Baggish, MD Dr. Baggish is Chairman of the Department of Obstetrics and Gynecology at Good Samaritan Hospital
More informationFrequency of menses. Duration of menses 3 days to 7 days. Flow/amount of menses Average blood loss with menstruation is 60-80cc.
Frequency of menses 24 days (0.5%) to 35 days (0.9%) Age 25, 40% are between 25 and 28 days Age 25-35, 60% are between 25 and 28 days Teens and women over 40 s cycles may be longer apart Duration of menses
More informationNot all roads point to hysterectomy: treatment options for fibroids
Not all roads point to hysterectomy: treatment options for fibroids MAUREEN KOHI, MD DEPARTMENT OF RADIOLOGY JEANNETTE LAGER, MD DEPARTMENT OF OBSTETRICS, GYNECOLOGY AND REPRODUCTIVE SCIENCES A lady, recently
More informationTwo-thirds of the almost one-half million
Minimally Invasive Surgery New data and the guidance of our professional societies are bringing us closer to clarity in understanding the superiority of minimally invasive techniques of hysterectomy Amy
More informationOffice hysteroscopy offers many benefits
MINIMALLY INVASIVE GYNECOLOGY How to reduce patient anxiety and pain during in-office hysteroscopy Amy L. Garcia, MD Dr. Garcia is Director, Center for Women s Surgery and Garcia Institute for Hysteroscopic
More informationHysteroscopy - current trends and challenges
J Obstet Gynecol India Vol. 58, No. 1 : January/February 2008 pg 57-62 Original Article Hysteroscopy - current trends and challenges Gour A, Zawiejska A, Mettler L Department of Obstetrics and Gynaecology,
More informationAnalysis of the Safety and Reliability of a Hydrothermal Ablation System
The Journal of Reproductive Medicine Analysis of the Safety and Reliability of a Hydrothermal Ablation System A Multicenter, Prospective Postmarket Study Jay M. Berman, M.D., David P. Krewson, D.O., Jeffrey
More informationNovasure as a Mechanical Endometrial Preparation Agent in Large Uteri
SCIENTIFIC PAPER Novasure as a Mechanical Endometrial Preparation Agent in Large Uteri Sushma Potti, MD, Shitanshu Uppal, MD, Ashwin J. Chatwani, MD, Enrique Hernandez, MD, Vani Dandolu, MD, MPH, MBA ABSTRACT
More informationCOLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS, SINGAPORE 2006
COLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS, SINGAPORE 2006 CONSENSUS STATEMENT ON THE MANAGEMENT AND EVALUATION OF MENORRHAGIA (INCLUDING MANAGEMENT OF FIBROIDS) Introduction Menorrhagia is defined as
More informationEndometrial line thickness in different conditions.
Endometrial line thickness in different conditions 1 Endometrial thickens in response to Rising estrogen levels during the menstrual cycle and then shedding endometrial at the times of menses 2 The thickens
More informationbleeding Studies naar de diagnostiek van endom triumcarcinoom bij vrouwen met postm nopauzaal bloedverlies. Studies on the
Studies on the diagnosis of endometria cancer in women with postmenopausal bleeding. Studies naar de diagnostiek va endometriumcarcinoom bij vrouwen m postmenopauzaal bloedverlies. Studies on the diagnosis
More informationDiagnostic Laparoscopy patient information from your surgeon & SAGES
Diagnostic Laparoscopy patient information from your surgeon & SAGES Diagnostic Laparoscopy 1 Diagnostic Laparoscopy About conventional colon surgery: Patients may be referred to surgeons because of an
More informationHysteroscopy. Department of Gynaecology. Patient information
Hysteroscopy Department of Gynaecology Patient information What is is a hysteroscopy? a Hysteroscopy? A hysteroscopy is a procedure during which the inside of the uterus (womb) is examined using a thin
More informationCOMPARING THE EFFICACY AND ACCEPTABILITY OF NOVASURE TM VERSUS CAVATERM TM PLUS IN DUB PATIENTS
: 1035-1045 ISSN: 2277 4998 COMPARING THE EFFICACY AND ACCEPTABILITY OF NOVASURE TM VERSUS CAVATERM TM PLUS IN DUB PATIENTS ZAHRA ASGARI 1, M.D., LEILI HAFIZI 2, M.D., FARIDEH HOSSEINZADEH 3, M.D., AZAM
More informationDipartimento Materno-Infantile Direttore : Paolo Puggina. Miomectomia laparoscopica indicazioni e limiti Giuseppe De Francesco
Dipartimento Materno-Infantile Direttore : Paolo Puggina Miomectomia laparoscopica indicazioni e limiti Giuseppe De Francesco The clinical dilemma is whether we treat all symptomatic uterine leiomyomas
More information5/5/2010 FINANCIAL DISCLOSURE. Abnormal Uterine Bleeding. Is This A Problem? About me % of visits to gynecologist
Abnormal Uterine FINANCIAL DISCLOSURE I HAVE NO FINANCIAL INTEREST IN ANY OF THE PRODUCTS MENTIONED IN MY PRESENTATION Bryan K. Rone, M.D. University of Kentucky Obstetrics and Gynecology May 5, 2010 About
More informationJed Hawe a,b, *, Jason Abbott c, David Hunter d, Graham Phillips d, Ray Garry d,e
BJOG: an International Journal of Obstetrics and Gynaecology April 2003, Vol. 110, pp. 350 357 A randomised controlled trial comparing the endometrial ablation system with the Nd:YAG laser for the treatment
More informationPRE-ASS ESSMENT. Endometrial Ablation for Menorrhagia
PRE-ASS ESSMENT No. 30 Feb 2004 Before decides to undertake a health technology assessment, a pre-assessment of the literature is performed. Pre-assessments are based on a limited literature search; they
More informationEndometrial Cancer Biopsy of the endometrium Evaluation of women of all ages
Endometrial Cancer Biopsy of the endometrium Evaluation of women of all ages Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Health System Ann Arbor, Michigan Cancer of the
More informationUterine artery embolisation for treating adenomyosis
Uterine artery embolisation for treating Issued: December 2013 guidance.nice.org.uk/ipg NICE has accredited the process used by the NICE Interventional Procedures Programme to produce interventional procedures
More informationPelvic Support Problems
AP012, April 2010 ACOG publications are protected by copyright and all rights are reserved. ACOG publications may not be reproduced in any form or by any means without written permission from the copyright
More informationPrevention, Diagnosis and Treatment of Gynecologic Cancers
Prevention, Diagnosis and Treatment of Gynecologic Cancers Jubilee Brown MD and Pamela T. Soliman MD, MPH Department of Gynecologic Oncology and Reproductive Medicine University of Texas MD Anderson Cancer
More informationManagement of Uterine Myomas
Management of Uterine Myomas Deidre D. Gunn, MD Assistant Professor Division of Reproductive Endocrinology & Infertility February 16, 2018 Disclosures I have no relevant financial relationships to disclose.
More informationENDOMETRIAL RESECTION FOR THE TREATMENT OF MENORRHAGIA ENDOMETRIAL RESECTION FOR THE TREATMENT OF MENORRHAGIA. Study Patients
ENDOMETRIAL RESECTION FOR THE TREATMENT OF MENORRHAGIA ENDOMETRIAL RESECTION FOR THE TREATMENT OF MENORRHAGIA HUGH O CONNOR, M.R.C.O.G., AND ADAM MAGOS, M.D. ABSTRACT Background Endometrial resection is
More informationOUTPATIENT OPERATIVE HYSTEROSCOPY
OUTPATIENT OPERATIVE HYSTEROSCOPY Martin Farrugia MD MRCOG East Kent Hospitals NHS Trust Concepts Can you do a diagnostic hysteroscopy in a clinic? Can you do a Pipelle biopsy without local anaesthesia?
More informationOver the past year, a few gems have been
UPDATE Abnormal uterine bleeding Howard T. Sharp, MD Dr. Sharp is Professor and Vice Chair for Clinical and Quality Activities, Department of Obstetrics and Gynecology, University of Utah Health Sciences
More informationProduct Information. Confidence that lasts
Confidence that lasts What is Mirena? Inhibition of sperm motility and function inside the uterus and the fallopian tubes, preventing fertilization (Videla-Rivero et al. 1987). Section of system Levonorgestrel
More informationEndometrial Ablation for Perimenopausal Menorrhagia
Endometrial Ablation for Perimenopausal Menorrhagia Kelly H. Roy, MD, and John H. Mattox, MD Menorrhagia and polymenorrhea are common complaints of perimenopausal women. Safe, effective, and minimally
More informationHysterectomy : A Clinicopathologic Correlation
Bahrain Medical Bulletin, Vol. 28, No.2, June 2006 Hysterectomy : A Clinicopathologic Correlation Layla S Abdullah, FRCPC* Objective : To study the most common pathologies identified in hysterectomy specimens
More informationGYNECOLOGY UPDATE IN. & Minimally Invasive Surgery. 6th Annual Collaborative Symposium
Mayo Clinic School of Continuous Professional Development 6th Annual Collaborative Symposium UPDATE IN GYNECOLOGY & Minimally Invasive Surgery In collaboration with BRIGHAM AND WOMEN S HOSPITAL Florida
More informationMedical treatment for uterine fibroids
Medical treatment for uterine fibroids Prof Mary Ann Lumsden Prof of Gynaecology and Medical Education University of Glasgow Senior Vice President RCOG Conflict of Interest Chair, Guideline development
More information(ARCHIVED: 12/20/01-05/18/05) CATEGORY: Technology Assessment. Proprietary Information of Excellus Health Plan, Inc.
MEDICAL POLICY SUBJECT: ENDOMETRIAL ABLATION EFFECTIVE DATE: 11/19/99 PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial
More informationHeavy Menstrual Bleeding. Mr Nick Nicholas MD FRCOG Grad Dip Law. Consultant Gynaecologist
Heavy Menstrual Bleeding Mr Nick Nicholas MD FRCOG Grad Dip Law. Consultant Gynaecologist Why is HMB so important? 1:20 women aged 30-49 consult their GP with HMB Once referred to gynaecologist, surgical
More informationOptional Hands-On Laparoscopic & Robotic Suturing Techniques Workshop October 5-6, 2009 PROGRAM SCHEDULE
22 nd ANNUAL ADVANCED TECHNIQUES IN ENDOSCOPIC AND ROBOTIC GYNECOLOGIC SURGERY Hyatt Regency Maui Resort & Spa Lahaina, Maui, Hawaii October 7-10, 2009 Optional Hands-On Laparoscopic & Robotic Suturing
More informationMENORRHAGIA TREATED BY THERMAL BALLOON ENDOMETRIAL ABLATION
, ORIGINAL RESEARCH,,,, MENORRHAGIA TREATED BY THERMAL BALLOON ENDOMETRIAL ABLATION Douglass B. Yackel, MD, FRCSC, Consultant Gynaecologist, Delta Hospital, Delta, British Columbia ABSTRACT RESUME One
More informationMenstrual Disorders & Ambulatory Gynaecology
Menstrual Disorders & Ambulatory Gynaecology Mr. Nagui Lewis Aziz M B, CH B, FRCOG Consultant Gynaecologist The Royal Oldham Hospital 01/09/2018 Heavy menstrual bleeding (HMB ) is a common problem responsible
More informationPhysician. Patient HYSTERECTOMY HYSTERECTOMY. Treatment Options Risks and Benefits Experience and Skill
HYSTERECTOMY Physician Treatment Options Risks and Benefits Experience and Skill Patient Personal Preferences Values and Concerns Lifestyle Choices HYSTERECTOMY Shared Decision Making A process of open
More informationPALM-COEIN: Your AUB Counseling Guide
PALM-COEIN: Your AUB Counseling Guide 10 million+ Treat the cause, not the symptom In the U.S, more than 10 million women between the ages of 35 and 49 are affected by AUB 1 Diagnosis Cause Structural
More informationClinical Policy: Endometrial Ablation Reference Number: CP.MP.106
Clinical Policy: Reference Number: CP.MP.106 Effective Date: 02/16 Last Review Date: 09/17 Revision Log Coding Implications See Important Reminder at the end of this policy for important regulatory and
More informationDiagnostic Features and Therapeutic Consequences of Hysteroscopy in Women with Abnormal Uterine Bleeding and Abortion
American Journal of Applied Sciences 9 (1): 13-17, 2012 ISSN 1546-9239 2012 Science Publications Diagnostic Features and Therapeutic Consequences of Hysteroscopy in Women with Abnormal Uterine Bleeding
More informationInvestigating HMB- an evidence based approach
BSGE Meeting: Contemporary management of heavy menstrual bleeding (HMB) in primary and secondary care: (7 th December 2018, RCOG) Investigating HMB- an evidence based approach T. Justin Clark MB ChB, MD(Hons),
More informationRole of diagnostic hysteroscopy in evaluation of abnormal uterine bleeding and its histopathological correlation
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Chaudhari KR et al. Int J Reprod Contracept Obstet Gynecol. 2014 Sep;3(3):666-670 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationEndometrial Ablation: Where Have We Been? Where Are We Going?
CLINICAL OBSTETRICS AND GYNECOLOGY Volume 49, Number 4, 736 766 r 2006, Lippincott Williams & Wilkins Endometrial Ablation: Where Have We Been? Where Are We Going? MALCOLM G. MUNRO, MD, FRCS(C), FACOG
More informationIs Outpatient Hysteroscopy the New Gold Standard?
Is Outpatient Hysteroscopy the New Gold Standard? McIlwaine K, Readman E, Ma T, Manwaring J, Ellett L, Hicks L, Porter J, Cameron M, Maher P. Mercy Hospital for Women, Melbourne, Australia Background Abnormal
More informationConsidering Surgery for Fibroids? Learn about minimally invasive da Vinci Surgery
Considering Surgery for Fibroids? Learn about minimally invasive da Vinci Surgery The Condition: Uterine Fibroid (Fibroid Tumor) A uterine fibroid is a benign (non-cancerous) tumor that grows in the uterine
More informationHysteroscopy Clinic. Patient Information. Women and Children - Gynaecology
8 Hysteroscopy Clinic Patient Information Women and Children - Gynaecology When a woman is first told that she has a gynaecological condition that requires further investigation at a specialised hospital
More informationShift your surgical ambition to surgical action
Dates: February 1-3, 2018 3th International Meeting ENDO-Dubai : Updates in Minimal Invasive surgery in Gynecology Shift your surgical ambition to surgical action AGENDA AT A GLANCE Thursday, February
More informationCorrelation of Endometrial Thickness with the Histopathological Pattern of Endometrium in Postmenopausal Bleeding
DOI 10.1007/s13224-014-0627-z ORIGINAL ARTICLE Correlation of Endometrial Thickness with the Histopathological Pattern of Endometrium in Postmenopausal Bleeding Singh Pushpa Dwivedi Pooja Mendiratta Shweta
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationCLINICAL PRESENTATION AND RADIOLOGY QUIZ QUESTION
Donald L. Renfrew, MD Radiology Associates of the Fox Valley, 333 N. Commercial Street, Suite 100, Neenah, WI 54956 2/12/2011 Radiology Quiz of the Week # 7 Page 1 CLINICAL PRESENTATION AND RADIOLOGY QUIZ
More informationCervical Cancer Treatment
Scan for mobile link. Cervical Cancer Treatment Cervical cancer overview Cervical cancer occurs in the cervix, the part of the female reproductive system that connects the vagina and uterus. Almost all
More informationAdvanced 3D Ultrasound Incorporating Fly Thru Virtual Imaging Promotes the Concept of Ultrasound Hysteroscopy
Advanced 3D Ultrasound Incorporating Fly Thru Virtual Imaging Promotes the Concept of Ultrasound Hysteroscopy Bill Smith Clinical Diagnostics Services, London, UK Introduction Conventional hysteroscopy
More informationBard: Continence Therapy. Stress Urinary Incontinence. Regaining Control. Restoring Your Lifestyle.
Bard: Continence Therapy Stress Urinary Incontinence Regaining Control. Restoring Your Lifestyle. Stress Urinary Incontinence Urinary incontinence is a common problem and one that can be resolved by working
More informationComparison of carbon dioxide and normal saline for uterine distension in outpatient hysteroscopy
FERTILITY AND STERILITY Copyright 1996 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Comparison of carbon dioxide and normal saline for uterine distension in outpatient
More informationIndex. B Bladder, injury of, Bowel, injury of, , Brachytherapy, for cervical cancer, 357 Burns, electrosurgical,
Perioperative Nursing Clinics 1 (2006) 375 379 Index Note: Page numbers of article titles are in boldface type. A Abdominal hysterectomy Acidosis, from insufflation, 323 Active electrode monitoring, in
More informationHysteroscopy. What you need to know. 139 Dumaresq Street Campbelltown Phone Fax
Hysteroscopy What you need to know 139 Dumaresq Street Campbelltown Phone 4628 5292 Fax 4628 0349 www.nureva.com.au September 2015 HYSTEROSCOPY AND DILATATION & CURETTAGE OF THE UTERUS Introduction I have
More informationYour visit to the Outpatient Hysteroscopy Clinic
Your visit to the Outpatient Hysteroscopy Clinic Department of Gynaecology Patient Information What What is the is an Outpatient outpatient Cystoscopy hysteroscopy? Clinic? An outpatient hysteroscopy means
More informationFertility Following Myomectomy
Fertility Following Myomectomy FRANCIS M. INGERSOLL, M.D. MYOMECTOMY is an operation frequently indicated in both the maitied and the single woman who desires to preserve her child-bearing function. The
More informationUTERINE FIBROID EMBOLIZATION
INTERVENTIONAL RADIOLOGY PROTOCOLS UTERINE FIBROID EMBOLIZATION Interventional Radiology Tower Health Medical Group offers the option to treat uterine fibroids with fibroid embolization (UFE), an alternative
More informationChronic Pelvic Pain. AP099, December 2010
AP099, December 2010 Chronic Pelvic Pain Pain in the pelvic area that lasts for 6 months or longer is called chronic pelvic pain. An estimated 15 20% of women aged 18 50 years have chronic pelvic pain
More informationSperm Survival in Women. Motile Sperm in the Fundus and Tubes of Surgical Cases
Sperm Survival in Women Motile Sperm in the Fundus and Tubes of Surgical Cases Boris B. Rubenstein, M.D., Ph.D.; Hermann Strauss, M.D.; Maurice L. Lazarus, M.D., and Henry Hankin, M.D. THE DURATION of
More informationUterine-Sparing Treatment Options for Symptomatic Uterine Fibroids
Uterine-Sparing Treatment Options for Symptomatic Uterine Fibroids Developed in collaboration Learning Objective Upon completion, participants should be able to: Review uterine-sparing fibroid therapies
More informationWOMEN S HEALTH SERVICES
WOMEN S HEALTH SERVICES Committed to enhancing the total well-being of women throughout their lives Knowledge-Powered Medicine 877-WSU-DOCS upgdocs.org/womenshealth WOMEN S HEALTH SERVICES UPG Women s
More information